The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2026 | Essential genomic tests and patient-centered treatment decisions in CLL
Mary Ann Anderson, MBBS, FRACP, FRCPA, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, discusses the role of TP53, del(17p), IGHV mutation status, and karyotypic complexity in guiding first-line treatment decisions for chronic lymphocytic leukemia (CLL). Dr Anderson highlights the practical challenges of accessing molecular testing and emphasizes the importance of patient preferences, comorbidities, and treatment duration when choosing between continuous BTK inhibition and fixed-duration venetoclax-based therapy. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
